Clinical Trial: A Study of YKST02 in Participants With Primary IgA Nephropathy

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498673) titled 'A Study of YKST02 in Participants With Primary IgA Nephropathy' on March 23.

Brief Summary: The goal of this clinical trial is to evaluate the safety and tolerability of YKST02 and to explore its potential to treat adults with primary IgA nephropathy (IgAN). The study will also assess how the drug moves through the body and how it affects the immune system.

The main questions it aims to answer are:

* Is YKST02 safe and well tolerated?

* Does YKST02 reduce protein levels in the urine?

* How does YKST02 behave in the body (pharmacokinetics, PK)?

* How does YKST02 affect the immune system (pharmacodynamics, PD)? Participants are ...